These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. Dama P; Tang M; Fulton N; Kline J; Liu H J Immunother Cancer; 2019 Jul; 7(1):175. PubMed ID: 31291985 [TBL] [Abstract][Full Text] [Related]
10. Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia - a prospective study of 20 paediatric patients. Eyrich M; Wiegering V; Lim A; Schrauder A; Winkler B; Schlegel PG Br J Haematol; 2009 Nov; 147(3):360-70. PubMed ID: 19694715 [TBL] [Abstract][Full Text] [Related]
11. A subset of virus-specific CD161 Alsuliman A; Muftuoglu M; Khoder A; Ahn YO; Basar R; Verneris MR; Muranski P; Barrett AJ; Liu E; Li L; Stringaris K; Armstrong-James D; Shaim H; Kondo K; Imahashi N; Andersson B; Marin D; Champlin RE; Shpall EJ; Rezvani K Blood; 2017 Feb; 129(6):740-758. PubMed ID: 27821506 [TBL] [Abstract][Full Text] [Related]
12. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Williams P; Basu S; Garcia-Manero G; Hourigan CS; Oetjen KA; Cortes JE; Ravandi F; Jabbour EJ; Al-Hamal Z; Konopleva M; Ning J; Xiao L; Hidalgo Lopez J; Kornblau SM; Andreeff M; Flores W; Bueso-Ramos C; Blando J; Galera P; Calvo KR; Al-Atrash G; Allison JP; Kantarjian HM; Sharma P; Daver NG Cancer; 2019 May; 125(9):1470-1481. PubMed ID: 30500073 [TBL] [Abstract][Full Text] [Related]
13. T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005. Ersvaer E; Hampson P; Hatfield K; Ulvestad E; Wendelbo Ø; Lord JM; Gjertsen BT; Bruserud Ø Cancer Immunol Immunother; 2007 Jun; 56(6):913-25. PubMed ID: 17115221 [TBL] [Abstract][Full Text] [Related]
14. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Gardner R; Wu D; Cherian S; Fang M; Hanafi LA; Finney O; Smithers H; Jensen MC; Riddell SR; Maloney DG; Turtle CJ Blood; 2016 May; 127(20):2406-10. PubMed ID: 26907630 [TBL] [Abstract][Full Text] [Related]
15. Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients. Govindaraj C; Tan P; Walker P; Wei A; Spencer A; Plebanski M Clin Cancer Res; 2014 Feb; 20(3):724-35. PubMed ID: 24297862 [TBL] [Abstract][Full Text] [Related]
16. Impaired B-cell reconstitution in children after chemotherapy for standard or medium risk acute precursor B-lymphoblastic leukemia. Wiegering V; Frank J; Freudenberg S; Morbach H; Schlegel PG; Eyrich M; Winkler B Leuk Lymphoma; 2014 Apr; 55(4):870-5. PubMed ID: 23786458 [TBL] [Abstract][Full Text] [Related]
17. [Efficacy of shenqi fuzheng injection combined with chemotherapy in treatment of acute leukemia and its effect on T-lymphocyte subsets, serum IFN-gamma, IL-10 and IL-2]. Wei YF; Wang SY; Ren LL Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Apr; 25(4):303-6. PubMed ID: 15892271 [TBL] [Abstract][Full Text] [Related]
19. The cellular immune system of patients with acute leukemia and severe chemotherapy-induced leukopenia: characterization of T lymphocyte subsets responsive to IL-16 and IL-17. Bruserud O; von Volkman HL; Ulvestad E Acta Haematol; 2000; 104(2-3):80-91. PubMed ID: 11154979 [TBL] [Abstract][Full Text] [Related]
20. Cyclosporine-induced autologous graft-versus-host disease in patients with acute myeloid leukemia undergoing non-myeloablative chemotherapy without progenitor cell reinfusion. Stein M; Feldman E; Seiter K; Chiao JW; Goff H; Baskind P; Beer M; Ahmed T Bone Marrow Transplant; 1999 Nov; 24(10):1073-7. PubMed ID: 10578157 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]